Dr. Jeremy M. Levin, DPhil, MB, BChir, became President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. on May 9, 2012.
Prior to joining Teva, Dr. Levin was a member of the Senior Management Team at Bristol-Myers Squibb (BMS) , as Senior Vice President of Strategy, Alliances and Transactions. He was responsible for the company’s global and “String of Pearls” strategies, as well as M&A, licensing, divestitures, and corporate and academic alliances. At the same time, Dr. Levin served as President and Director of two wholly-owned BMS subsidiaries.
Before joining BMS, Dr. Levin served as the Global Head of Strategic Alliances at Novartis Institutes of Biomedical Research, where he managed alliances with academia and biotechnology, and established strategic collaborations. In addition, Dr. Levin has served on the executive committees and boards of numerous internationally renowned bioscience, biotechnology, venture fund and research organizations.
He holds a BA in Zoology from Oxford, and an MA and doctorate (DPhil) in Cell Biology and Chromatin Structure from the University of Oxford. He also holds an MB, BChir degree (Bachelor of Medicine, Bachelor of Surgery) from the University of Cambridge. He resides in Israel.